These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33144090)

  • 1. Up-regulated microRNA-218-5p ameliorates the damage of dopaminergic neurons in rats with Parkinson's disease via suppression of LASP1.
    Ma X; Zhang H; Yin H; Geng S; Liu Y; Liu C; Zhao J; Liu Y; Wang X; Wang Y
    Brain Res Bull; 2021 Jan; 166():92-101. PubMed ID: 33144090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of lncRNA BACE1-AS improves dopamine-dependent oxidative stress in rats with Parkinson's disease by upregulating microRNA-34b-5p and downregulating BACE1.
    Li Y; Fang J; Zhou Z; Zhou Q; Sun S; Jin Z; Xi Z; Wei J
    Cell Cycle; 2020 May; 19(10):1158-1171. PubMed ID: 32308102
    [No Abstract]   [Full Text] [Related]  

  • 3. MicroRNA-185 activates PI3K/AKT signalling pathway to alleviate dopaminergic neuron damage via targeting IGF1 in Parkinson's disease.
    Qin X; Zhang X; Li P; Wang M; Yan L; Pan P; Zhang H; Hong X; Liu M; Bao Z
    J Drug Target; 2021 Sep; 29(8):875-883. PubMed ID: 33560148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulated long non-coding RNA RMST ameliorates dopaminergic neuron damage in Parkinson's disease rats via regulation of TLR/NF-κB signaling pathway.
    Ma X; Wang Y; Yin H; Hua L; Zhang X; Xiao J; Yuan Q; Wang S; Liu Y; Zhang S; Wang Y
    Brain Res Bull; 2021 Sep; 174():22-30. PubMed ID: 33933526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulated expression of microRNA-329 inhibits apoptosis of nigral dopaminergic neurons by regulating CDKN2D expression via the FoxO3a signaling pathway in rats with Parkinson's disease.
    Liu YY; Zhang YN; Yang QS
    J Cell Physiol; 2018 Nov; 233(11):8617-8629. PubMed ID: 29761857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of microRNA-375 ameliorates the damage of dopaminergic neurons, reduces oxidative stress and inflammation in Parkinson's disease by inhibiting SP1.
    Cai LJ; Tu L; Li T; Yang XL; Ren YP; Gu R; Zhang Q; Yao H; Qu X; Wang Q; Tian JY
    Aging (Albany NY); 2020 Jan; 12(1):672-689. PubMed ID: 31927536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of lncRNA UCA1 ameliorates the damage of dopaminergic neurons, reduces oxidative stress and inflammation in Parkinson's disease through the inhibition of the PI3K/Akt signaling pathway.
    Cai L; Tu L; Li T; Yang X; Ren Y; Gu R; Zhang Q; Yao H; Qu X; Wang Q; Tian J
    Int Immunopharmacol; 2019 Oct; 75():105734. PubMed ID: 31301558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-218-5p-Ddx41 axis restrains microglia-mediated neuroinflammation through downregulating type I interferon response in a mouse model of Parkinson's disease.
    Wang D; Gao H; Qin Q; Li J; Zhao J; Qu Y; Li J; Xiong Y; Min Z; Mao Z; Xue Z
    J Transl Med; 2024 Jan; 22(1):63. PubMed ID: 38229084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Mechanism of SNHG8/Microrna-421-3p/Sorting Nexin 8 Axis on Dopaminergic Neurons in Substantia Nigra in a Mouse Model of Parkinson's Disease.
    Zhou S; Zhou X; Jiang Z; Ma J; Li Y; Qian Z; Li H
    Neurochem Res; 2023 Mar; 48(3):942-955. PubMed ID: 36401052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circular RNA circTLK1 regulates dopaminergic neuron injury during Parkinson's disease by targeting miR-26a-5p/DAPK1.
    Chen W; Hou C; Wang Y; Hong L; Wang F; Zhang J
    Neurosci Lett; 2022 Jun; 782():136638. PubMed ID: 35447224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acrolein acts as a neurotoxin in the nigrostriatal dopaminergic system of rat: involvement of α-synuclein aggregation and programmed cell death.
    Wang YT; Lin HC; Zhao WZ; Huang HJ; Lo YL; Wang HT; Lin AM
    Sci Rep; 2017 Apr; 7():45741. PubMed ID: 28401906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
    Kanagaraj N; Beiping H; Dheen ST; Tay SS
    Neuroscience; 2014 Jul; 272():167-79. PubMed ID: 24792712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Estrogen protects the dopaminergic neurons in substantia nigra against damage induced by 6-hydroxydopamine].
    Meng JL; Ma YY; Luo HY; Kong SZ; He YW; Dong BC; Wu SH; He M
    Sheng Li Xue Bao; 2008 Jun; 60(3):369-74. PubMed ID: 18560728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.
    Khodr CE; Becerra A; Han Y; Bohn MC
    Brain Res; 2014 Mar; 1550():47-60. PubMed ID: 24463035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.
    Boshoff EL; Fletcher EJR; Duty S
    Neuropharmacology; 2018 Jul; 137():156-163. PubMed ID: 29698669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. microRNA-221 rescues the loss of dopaminergic neurons in a mouse model of Parkinson's disease.
    Yao Y; Zhao Z; Zhang F; Miao N; Wang N; Xu X; Yang C
    Brain Behav; 2023 Mar; 13(3):e2921. PubMed ID: 36795044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
    Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
    Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of microRNA-342-3p increases glutamate transporters and prevents dopaminergic neuron loss through activating the Wnt signaling pathway via p21-activated kinase 1 in mice with Parkinson's disease.
    Wu DM; Wang S; Wen X; Han XR; Wang YJ; Shen M; Fan SH; Zhuang J; Zhang ZF; Shan Q; Li MQ; Hu B; Sun CH; Lu J; Chen GQ; Zheng YL
    J Cell Physiol; 2019 Jun; 234(6):9033-9044. PubMed ID: 30362546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease.
    Yang XY; Zhao EY; Zhuang WX; Sun FX; Han HL; Han HR; Lin ZJ; Pan ZF; Qu MH; Zeng XW; Ding Y
    Neurol Sci; 2015 Nov; 36(11):2027-33. PubMed ID: 26169757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.